Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Value Expansion And Long-Term Growth Outlook

The asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market size has experienced significant expansion in recent years. It is projected to increase from $9.44 billion in 2025 to $10.23 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.4%. Historically, this growth has been driven by factors including the escalating prevalence of smoking-related respiratory disorders, the increasing misdiagnosis of asthma and COPD overlap conditions, limitations in treatment personalization within respiratory care, a rise in hospital admissions due to exacerbations, and a continued reliance on conventional inhalation therapies.

The asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market size is projected to experience substantial expansion in the coming years. Its value is anticipated to reach $14.27 billion by the year 2030, demonstrating a compound annual growth rate (CAGR) of 8.7%. This projected increase during the forecast period is fueled by several factors, including the wider application of biologics in managing respiratory conditions, the growing embrace of digital devices for respiratory monitoring, an increased need for tailored treatment plans, the expansion of home-based chronic disease care, and improvements in anti-inflammatory therapies that are more targeted. Key developments expected throughout this period encompass personalized precision therapies designed for asthma-COPD overlap phenotypes, enhanced digital monitoring for inhaler adherence alongside integrated respiratory care, a surge in biologic-based treatments addressing eosinophilic airway inflammation, the incorporation of remote patient monitoring into chronic respiratory disease management, and a move towards combination inhalation therapies for superior airway control.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample_request?id=38698593&type=smp

Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Development Factors: Which Trends Are Supporting Demand?

An increase in cases linked to smoking is projected to fuel the expansion of the asthma chronic obstructive pulmonary disease (COPD) overlap treatment market in the coming years. These smoking-driven cases denote respiratory illnesses, like asthma or COPD, predominantly caused by tobacco consumption. The rise in such cases stems from a growing population of tobacco users, leading to lung inflammation, damage to airways, and an elevated risk of severe respiratory conditions. Asthma-COPD overlap treatment tackles these smoking-induced conditions by offering specialized therapies that concurrently manage the associated symptoms, restricted airflow, and lung deterioration from tobacco use, thereby enhancing lung function and patient well-being for individuals with both asthma and COPD. For example, in February 2026, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that chronic obstructive pulmonary disease (COPD) accounted for 3.7% of Australia’s overall disease burden in 2024 and was responsible for 7,437 deaths in 2023, equating to 28 deaths per 100,000 people and making up 4.1% of all deaths. Consequently, the surge in smoking-related cases is anticipated to drive the growth of the asthma COPD overlap treatment market.

Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Segment Analysis: What Are The Major Market Categories?

The asthma-chronic obstructive pulmonary disease (copd) overlap treatment market covered in this report is segmented –

1) By Drug Class: Triple Therapy, Dual Therapy, Biologics, Systemic Therapies

2) By Treatment Use Case: Exacerbation Prevention In Asthma Chronic Obstructive Pulmonary Disease Overlap Phenotypes, Severe Asthma With Fixed Airflow Limitation, Chronic Obstructive Pulmonary Disease With Eosinophilic Inflammation, Post Hospital Discharge Optimization, Comorbidity Driven Management

3) By Route Of Administration: Inhalation, Oral

4) By Patient Age Group: Pediatric, Adult, Geriatric

5) By End User: Retail Pharmacy Channel, Hospitals, Pulmonology Clinics, Primary Care Centers, Other End Users

Subsegments:

1) By Triple Therapy: Inhaled Corticosteroid Long Acting Beta Agonist Long Acting Muscarinic Antagonist Combinations, Fixed Dose Combination Inhalers, Maintenance Therapy Combinations

2) By Dual Therapy: Inhaled Corticosteroid Long Acting Beta Agonist Combinations, Long Acting Beta Agonist Long Acting Muscarinic Antagonist Combinations, Add On Bronchodilator Combinations

3) By Biologics: Interleukin Five Inhibitors, Interleukin Four And Interleukin Thirteen Pathway Inhibitors, Immunoglobulin E Targeting Therapies, Monoclonal Antibody Treatments

4) By Systemic Therapies: Oral Corticosteroids, Systemic Bronchodilators, Anti Inflammatory Agents, Immune Modulating Therapies

Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Leading Companies Driving Competitive Growth

Major companies operating in the asthma-chronic obstructive pulmonary disease (copd) overlap treatment market are Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca PLC, GlaxoSmithKline plc, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Grifols S. A., Sun Pharmaceutical Industries Limited, Chiesi Farmaceutici S. p. A., Kyowa Kirin Co. Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Theravance Biopharma Inc., Orion Corporation

Access The Complete Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/asthma-chronic-obstructive-pulmonary-disease-copd-overlap-treatment-market-report

Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model